Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.
After a first lobar haemorrhage from amyloid angiopathy, the question is what happens next. Recurrence, survival, and cognition each carry their own numbers.
Rebleeding is common and front-loaded. About one quarter of survivors experience a recurrent haemorrhage (pooled 23%, 95% CI 18-28%). Risk rises with a prior haemorrhage, convexity subarachnoid blood, cortical superficial siderosis (especially disseminated), severe centrum-semiovale perivascular spaces, and a larger index bleed.
Roughly half of survivors reach a favourable functional outcome at around a year and a half, while about one fifth to one quarter die. Poor outcome tracks with a lower admission consciousness level, recurrent bleeding, severe white-matter disease, and marked brain atrophy. These figures come from a single-centre cohort, so they guide counselling rather than individual prediction.
Dementia is the third trajectory. Among patients without early dementia after a lobar bleed, about one quarter develop dementia within a median of 2.5 years. Conversion is more likely with pre-existing mild cognitive impairment, heavy white-matter hyperintensity burden, disseminated siderosis, and a higher total small-vessel score. Cognitive decline also occurs in amyloid angiopathy without any haemorrhage, so dementia is not purely a post-bleed event.
Counselling has a unifying frame. Amyloid angiopathy and hypertensive arteriolosclerosis together account for the great majority of spontaneous brain haemorrhages. Both create vessels in which antithrombotic drugs raise bleeding risk. Recurrence numbers and a medication review therefore belong in the same conversation. No primary-prevention strategy beyond vascular risk-factor control, principally blood pressure, has evidence behind it.
Evidence anchors
- Jia et al. 2023, risk factors for recurrent CAA-related intracerebral haemorrhage meta-analysis: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1265693/full
- Che et al. 2022, long-term outcome of CAA-related haemorrhage: https://pmc.ncbi.nlm.nih.gov/articles/PMC9532921/
- Xiong et al. 2019, predictors of late post-haemorrhage dementia in probable CAA: https://pmc.ncbi.nlm.nih.gov/articles/PMC9301963/
- Greenberg et al. 2022, guideline for the management of patients with spontaneous intracerebral haemorrhage: https://www.ahajournals.org/doi/10.1161/STR.0000000000000407/
- Jakel et al. 2022, prevalence of cerebral amyloid angiopathy systematic review and meta-analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC9290643/